Seeking Alpha

The FDA has withdrawn approval of Impax (IPXL -1%) and Teva's (TEVA -0.5%) Budeprion XL 300 mg,...

The FDA has withdrawn approval of Impax (IPXL -1%) and Teva's (TEVA -0.5%) Budeprion XL 300 mg, saying it's reviewed new data that indicates it's not therapeutically equivalent to Wellbutrin XL 300 mg. Both companies have stopped shipping the product and are issuing detailed information to their customers. The FDA added that its announcement does not affect the Impax/Teva Budeprion 150 mg product or generic Budeprion products made by other manufacturers.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector